Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Is The Predicted Market Size Of The Antispasmodics Drugs Industry By 2029?
The market size for antispasmodics medicines has significantly expanded in the past few years. The projections show the market, which is valued at $13.76 billion in 2024, escalating to $14.93 billion in 2025 with a compound annual growth rate (CAGR) of 8.5%. The historic growth is connected to increased occurrence of spasmodic conditions, advances in medical study, an expanding elderly population, shifting life habits, and advancements in diagnostics capabilities.
The market for antispasmodics drugs is forecasted to experience robust growth in the forthcoming years, reaching “$21.44 billion by 2029 with a compound annual growth rate (CAGR) of 9.5%. This growth during the predicted period is due to factors such as increased healthcare spending, personalized healthcare approaches, worldwide population expansion, developing markets, and advancements in clinical trials and research. Key trends to watch during this forecast period encompass the broadening of indications for antispasmodics, improvements in healthcare infrastructure, progression in drug development, heightened awareness and diagnosis, and a preference for non-invasive treatment procedures.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9414&type=smp
What Drivers Are Accelerating Expansion Of The Antispasmodics Drugs Market?
The rise in the elderly population is anticipated to drive the growth of the antispasmodic drug market. Individuals who are 65 years old and above are deemed as elderly and they are often associated with various physical and mental health problems. Antispasmodic drugs are utilized to manage symptoms linked to conditions leading to muscle spasms or cramps, and can also be used for certain conditions like irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For example, data from the World Health Organization (WHO), a Switzerland-based entity in charge of international public health, showed that by October 2022, the global population aged 60 and older will soar to 1.4 billion by 2030. There will be a twofold rise in the global population aged 60 and above by 2050 (2.1 billion). The population of those aged 80 and above is expected to see a significant surge by 2050, reaching 426 million. Consequently, the boost in the elderly population will stimulate the antispasmodic drug market.
Which Sub-Segments Are Driving Growth Within The Antispasmodics Drugs Market?
The antispasmodics drugs market covered in this report is segmented –
1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs
2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations
2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations
3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics
What Future-Focused Trends Are Anticipated In The Antispasmodics Drugs Market?
A dominant trend observed in the current antispasmodic drugs market is product innovation. Major participants in the market are continuously focusing on creating inventive strategies to solidify their market presence. For example, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, announced the launch of IBSRELA, an NHE-3 inhibitor intended for the treatment of patients suffering from irritable bowel syndrome with constipation (IBS-C). This product stands out in the market due to its unique new way of treatment, coupled with its impressive efficiency. It successfully manages constipation and various stomach symptoms common in IBS-C patients, as demonstrated in Phase 3 clinical trials.
Which Organizations Are At The Forefront Of The Antispasmodics Drugs Market?
Major companies operating in the antispasmodics drugs market include Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/antispasmodics-drugs-global-market-report
Which Region Dominates The Antispasmodics Drugs Market Today?
North America was the largest region in the antispasmodics drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=9414&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
